Docket Report: Hikma Pharmaceuticals USA v. Amarin Pharma

Note: I am catching up on cases argued since April and descriptions will be (very) brief and incomplete. Predictions based on the same model used for other cases. Question of whether a generic drugmaker that uses an FDA-approved abbreviated label (that omits the brand-name) can still be liable for inducing patent infringement based on its label, press releases, and marketing that allegedly encourage doctors to prescribe the generic for the patented use. The Federal Circuit allowed the claim of patent infringement. The model predicts the Court reverses.